by Symmetron | Jan 21, 2019
Cancer An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom Value in Health. 2008;11(5):791-9 Authors Brown B, Diamantopoulos A, Bernier J,...
by Symmetron | Jan 19, 2019
Venous Thromboembolism  Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective Journal of Medical Economics. 2012;15(5):817-28 Authors McDonald H, Diamantopoulos A, Wells P,...
by Symmetron | Jan 17, 2019
Venous Thromboembolism Cost-Effectiveness of Rivaroxaban versus Enoxaparin for the Prevention of Postsurgical Venous Thromboembolism in Canada Thrombosis and Haemostasis. 2010;104(4):760-70 Awards Top Pharmacoeconomics article of 2018! Publications in other disease...
Recent Comments